Patients with pancreatic cancer (PDAC) and pathogenic variants (PVs) in BRCA1 or BRCA2 have historically been grouped together.1,2 However, preclinical and clinical data in other BRCA-related tumors suggests that the biological implications of BRCA1 and BRCA2 PVs may be different.3,4,5 To explore this further, we compared outcomes of patients with BRCA1 vs BRCA2-related PDAC using 2 large data sets. This evidence concerns the gene BRCA1 and familial pancreatic carcinoma.